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Summary Regionally-administered, drug-loaded microspheres have a potential role in the treatment of renal
tumours. Vasoactive agents, for example, angiotensin II, may allow selective delivery of microspheres to
tumour. The present study defines the regional advantage that may be obtained from angiotensin II by
quantifying tumour and normal kidney blood flow using radiolabelled microsphere renal perfusion studies and
per-operative laser-doppler flow measurements. Angiotensin II increased microsphere distribution to tumour,
relative to normal kidney, by a factor of four. This enhancement was associated with an absolute increase in
tumour blood flow.
Renal carcinoma accounts for 2-3% of all adult malignan-
cies. The majority of patients have no evidence of metastases
at the time of initial presentation (Patel & Lavengood, 1978);
nephrectomy is the treatment of choice. However, an alterna-
tive approach may be indicated in patients who are not
considered suitable or fit for surgery and who have trouble-
some symptoms related to the primary tumour.
The results of systemic chemotherapy for renal neoplasms
have been disappointing. Attempts to improve response rates
have been limited to toxicity (Harris, 1983). Attention has
therefore turned to the concept of regional therapy with the
intention of delivering high doses of therapeutic agents
directly to tumour with minimal systemic exposure.
We have previously shown that the selective administration
ofcytotoxic-loaded albumin microspheres via the renal artery
produces high concentrations of drug within the kidney
(McArdle et al., 1988; Kerr et al., 1988). Further modifica-
tions are required in order to target therapeutic microspheres
specifically to tumour tissue. Previous studies have suggested
that an infusion of a vasoactive agent, such as angiotensin II,
results in a redistribution of arterial blood flow and its
contents away from normal tissues and towards tumour.
These blood flow changes therefore produce a method of
targeting cytotoxic loaded microspheres towards tumour.
The aim of the present study was to quantitate the degree
of targeting of regionally administered albumin microspheres
which could be achieved following an angiotensin II infusion
via the renal artery.
Materials and methods
Patient
A 57 year old male presented with lower abdominal pain and
constipation. Barium enema examination failed to show any
colonic pathology. However, a left, paravertebral soft tissue
shadow was noted. Subsequent ultrasound scan demonstrat-
ed a tumour in the left kidney. There was no evidence of
metastases. The patient was therefore prepared for renal
angiography to be followed by nephrectomy.
Study design
The effects of an angiotensin II infusion were studied using
the following techniques: (i) During angiography, radio-
labelled microspheres were introduced into the renal artery,
before and after an angiotensin II infusion. Microsphere
distribution was subsequently studied using scintigraphy; (ii)
At nephrectomy, tumour blood flow was recorded, before
and after an angiotensin II infusion, with a laser-doppler
flowmeter; (iii) Following nephrectomy, the kidney under-
went further scintigraphy to measure microsphere distribu-
tion; (iv) Tumour and normal kidney biopsies were counted
in a well gamma counter.
Microsphere preparation
Two aliquots of albumin microspheres were prepared for
perfusion studies and radiolabelled with either 3''I or 'Tc.
Albumin microspheres for radiolabelling with "'lI were
prepared as previously described (Willmott et al., 1985). The
microspheres were 25-351tm mean diameter as assessed by
laser diffraction measurements. To 10 mg of microspheres
(2 x 106 particles) were added 10 MBq of Na(`31I).
Albumin microspheres for radiolabelling with 9'Tc were
prepared using a TCK5 kit (CIS) to produce 5 ml of 104
microspheres, 23-45 ytm diameter, radiolabelled with 80 MBq
`Tc.
Both sets of microspheres were prepared under sterile con-
ditions and radiolabelled 3 h prior to administration. Radio-
activity was referenced for the time ofdelivery to the patient.
Angiography
Under local anaesthesia, a selective left renal arteriogram was
obtained, using the Seldinger technique, after cannulation of
the right femoral artery. An accessory artery was demon-
strated supplying the inferior pole of the kidney.
A 5 ml suspension of 106 '3'I radiolabelled albumin micro-
spheres was then delivered to the renal artery as a 30 s bolus.
The patient then received a 3 ml infusion of angiotensin II
(5 iLg ml-') over 90s and this was immediately followed by
5 ml of 104 9'9Tc radiolabelled albumin microspheres over
30s.
In vivo imaging
Thirty minutes after angiography, the patient's abdomen was
imaged anteriorly and posteriorly in 13'I and 9'Tc channels
using an IGE 400A gamma camera with a high energy
parallel collimator for 180 s for each view. Images were
stored on a Link Analytical MAPS 2000 computer in 128 x
128 resolution. Anterior views of the chest were also taken in
the two energy channels. An index of the degree of shunting
of microspheres to the systemic circulation was calculated by
comparing the counts from the anterior views of both lungs
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with the geometric mean of the anterior and posterior counts
from the kidney using the equation:
Lung counts x 100 per cent
Renal counts x lung counts
Surgery
One hour after in vivo imaging, the patient underwent left
kidney exploration under general anaesthetic. Baseline blood
flow to the tumour was recorded in arbitrary 'perfusion
units' using a laser-doppler flowmeter (Periflux PF3 with
standard probe, Perimed, Sweden). Tumour blood flow was
continuously recorded during and after a further angiotensin
II infusion. This procedure was repeated, after repositioning
the flowmeter probe, and the angiogram catheter was remov-
ed. The patients then proceeded to nephrectomy. The kidney
was split in the coronal plant (Figure 1). The tumour
appeared to consist of an area of viable tissue immediately
medial to a gelatinous area of apparently, non-viable tissue.
Imaging ofkidney after nephrectomy
The kidney was taken back to the gamma camera immedi-
ately after resection and further images in 131I and 99mTc
channels were recorded over 60 s. After imaging, one, 1 ml
sample from the normal superior pole of kidney, the 'viable'
tumour and the 'non-viable' tumour were counted in a
Packard 5650 well gamma counter in 131I and 99ITc channels.
After correction for spillover from "3'I and 'Tc channels,
results were expressed as counts per minute per gram of
tissue. Statistical counting precision was better than 0.2%.
Regions ofinterest
The in vivo and post-resection gamma camera images were
compared with the photograph of the kidney and regions of
interest (ROI) of identical size and shape were plotted on
each image over normal superior pole of kidney, 'viable'
tumour and 'non-viable' tumour. ROI representing the lung
fields were drawn on the anterior chest image. Total counts
were summed in all ROI and expressed as total counts per
minute in each region.
Results
Gamma camera imaging
The post-resection posterior images of the right kidney are
illustrated in Figure 1. The results of analysis of the ROI are
shown in Table I. The 'viable' tumour: normal ratio of
microsphere distribution was 1.1 in vivo and 1.4 post-resec-
tion before angiotensin II and 2.8 in vivo and 3.8 post-
resection after angiotensin. In this patient therefore,
angiotensin II appears to increase viable tumour blood flow,
relative to that of normal kidney, by a factor of 2.5 on the in
vivo scans and by 2.6 on the post-resection scans. Similar
results were obtained when analysing the anterior views of
the kidney in which background activity and scattering were
more significant in vivo.
The ratio of counts from both lungs to the counts from the
kidney was 8.9% for the 99ITc channel and for '31I it was
10.6%. For 9"Tc, thyroid uptake was 1% of kidney counts
and "3'I thyroid uptake was 4% of kidney counts.
Laser-doppler recordings
For the two laser-doppler recordings, mean blood flow to
tumour was 32 perfusion units, increasing to 40 perfusion
units after angiotensin II on the first recording and 50 per-
fusion units, increasing to 100 perfusion units after angioten-
sin II on the second recording. The rise in tumour blood flow
was noted 20 s after the commencement of the angiotensin II
Table I Distribution ofmicrospheres
Pre-AII Post-AII
(131j) (99Tc)




Normal kidney 2078 10498
'Viable' tumour 2333 1.1 29302 2.8 2.5




Normal kidney 1218 5700
'Viable' tumour 1759 1.4 21713 3.8 2.6
'Non-viable' tumour 968 0.8 8486 1.5 1.9
Tissue samples
Counts/min/gram
Normal kidney 593699 309964
'Viable' tumour 863057 1.5 1790458 5.8 4.0
'Non-viable' tumour 515532 1.4 585941 1.9 1.4
infusion and this rise lasted for 50 and 120 s respectively for
the two recordings.
Well counts
The results of well gamma counting are shown in Table I.
Sample weights were; normal superior pole: 0.33 g, 'viable'
tumour: 0.47 g and 'non-viable' tumour: 0.22 g. The tumour:
normal ratio increased from 1.5 to 5.8 after angiotensin II;
i.e. an enhancement by a factor of four.
Histology
Microscopic examination demonstrated an adenocarcinoma.
Albumin microspheres could be clearly seen embolised in the
afferent arterioles, glomerular capillary loops and tumour
capillaries.
Discussion
Locoregional cancer therapy employs the principle of target-
ing treatment to tumours whilst minimising systemic expo-
sure. Targeting may occur at three levels. First level targeting
limits treatment to the kidney. Second level targeting confines
the therapeutic agent to the tumour mass. Third level target-
ing selectively delivers therapy to malignant cells (Widder et
al., 1979). The incorporation of therapeutic agents into
embolising particles, which are subsequently administered via
the renal artery, allows first level targeting. Previous studies
have used radioactive pellets or microencapsulated mito-
mycin C for adjuvant or palliative treatment of renal
tumours in humans (Lang, 1971; Kato et al., 1981). Tumour
shrinkage, symptomatic relief and reduced systemic exposure
to the cytotoxic agents have been reported. Animal studies of
regionally administered adriamycin-loaded albumin micro-
spheres have revealed a high renal entrapment (97%), with
subsequent release of drug by diffusion and biodegredation
of the albumin matrix over 48 h, resulting in reduced
systemic exposure to the antineoplastic agent (Kerr et al.,
1988; Willmott et al., 1985). Whilst these studies have been
successful in so far as targeting the kidney is concerned,
further measures are required to optimise the delivery of
cytotoxic drugs to the tumour rather than normal renal
tissue.
Abrams (1964) demonstrated angiographically, in a patient
with a hypernephroma, that an arterial infusion of epine-
phrine redistributes renal arterial blood flow. Ekelund et al.
(1972) employed similar principles using angiotensin II to
increase the diagnostic accuracy of renal angiography. On
exposure to vasoactive agents, arterioles supplying normalTARGETED THERAPY FOR RENAL CARCINOMA 367
Figure 1 Four posterior images ofleft kidney in indentical orientation and scale. Top left: posterior view ofcoronal section ofleft kidney. Top right: line drawing of coronal section of left kidney; 1: normal superior pole; 2: 'viable' tumour; 3: 'non-viable'
tumour; 4: normal inferior pole. Bottom left: post-resection gamma camera image of the distribution of microspheres delivered before angiotensin II. Bottom right: post-resection gamma camera image of the distribution of microspheres delivered after angiotensin II.
tissue constrict whereas tumour blood vessels, which lack
smooth muscle, remain dilated. This process therefore diverts
renal blood flow and its contents away from normal tissue
towards tumour. Lang (1970) used these techniques to deliver
therapeutic radioactive pellets to renal tumours. Therefore
these techniques allow second level targeting. Our previous
pilot experiments, on three renal carcinoma patients, showed
that the ratio of radiolabelled microspheres delivered to
tumour compared with normal kidney, following an angio-
tensin II infusion, was 2.5:1, 3:1 and 7.3:1 respectively
(unpublished data). Prior to the present study, the improve-
ment in tumour: normal ratio, compared with pre-angio-
tensin II distribution, was not known. Our results suggest
that angiotensin II may improve targeting of renal tumours
by 4-fold.
Although radiolabelled microsphere distribution studies
reveal changes in blood flow to tumour relative to normal
tissue, they do not explain whether these observations are
secondary to a decrease in blood flow to normal kidney,
increased blood flow to tumour or a combination of both368 J.H. ANDERSON et al.
these factors. The introduction of laser-doppler flow equip-
ment has allowed a dynamic study of tissue flow which has
revealed an absolute increase in blood flow to tumour follow-
ing angiotensin II infusion. Unfortunately, we did not
possess two probes, therefore we were able to measure simul-
taneously blood flow to normal kidney and tumour.
In this experiment blood flow was studied using four tech-
niques; in vivo perfusion scan, post-resection perfusion scan,
tissue well gamma counting and laser-doppler measurements.
It is interesting to note that all these methods produced
similar results. Therefore in vivo renal arterial perfusion
scintigraphy reasonably estimates the relative distribution of
microspheres to tumour relative to normal kidney. However,
the well gamma counts revealed a greater enhancement of
tumour: normal ratio than the post-resection scan which, in
turn, produced a higher ratio than the in vivo scan. These
observations may be explained by increased scatter due to
the kidney being further from the gamma camera on the in
vivo scan compared with the post-resection scan. Further-
more, the gamma camera only gives a two dimensional
analysis of the kidney (therefore the 'tumour' ROI includes
normal tissues anterior and posterior to the tumour) whereas
the well counts reflect activity in tumour alone. The well
counts, therefore, probably give the most accurate reflection
of tumour: normal kidney ratio enhancement. The accuracy
of gamma camera imaging may be improved by employing
tomographic techniques.
The albumin microspheres in normal kidney were seen to
enibolise in the afferent arterioles and glomerular capillary
loops. The mean biological half-time of these microspheres
has been shown to be 2.4 days (Goldberg et al., 1991) and it
is therefore likely that these glomeruli would undergo subse-
quent ischaemic necrosis. Angiotensin II should diminish this
problem but it should be born in mind when considering the
treatment of patients who have poor renal function or whose
contralateral kidney is absent or abnormal.
In conclusion, angiotensin II infusion improves the target-
ing of regionally administered albumin microspheres to renal
tumours. The use of cytotoxic loaded albumin microspheres
in the management of renal tumours merits further study.
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